Literature DB >> 24375753

Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

Kelly A Diggs-Andrews1, Jacquelyn A Brown, Scott M Gianino, Joshua B Rubin, David F Wozniak, David H Gutmann.   

Abstract

OBJECTIVE: Children with neurofibromatosis-1 (NF1) are at risk for developing numerous nervous system abnormalities, including cognitive problems and brain tumors (optic pathway glioma). Currently, there are few prognostic factors that predict clinical manifestations or outcomes in patients, even in families with an identical NF1 gene mutation. In this study, we leveraged Nf1 genetically engineered mice (GEM) to define the potential role of sex as a clinically relevant modifier of NF1-associated neuronal dysfunction.
METHODS: Deidentified clinical data were analyzed to determine the impact of sex on optic glioma-associated visual decline in children with NF1. In addition, Nf1 GEM were employed as experimental platforms to investigate sexually dimorphic differences in learning/memory, visual acuity, retinal ganglion cell (RGC) death, and Nf1 protein (neurofibromin)-regulated signaling pathway function (Ras activity, cyclic adenosine monophosphate [cAMP], and dopamine levels).
RESULTS: Female patients with NF1-associated optic glioma were twice as likely to undergo brain magnetic resonance imaging for visual symptoms and 3× more likely to require treatment for visual decline than their male counterparts. As such, only female Nf1 GEM exhibited a decrement in optic glioma-associated visual acuity, shorter RGC axons, and attenuated cAMP levels. In contrast, only male Nf1 GEM showed spatial learning/memory deficits, increased Ras activity, and reduced dopamine levels.
INTERPRETATION: Collectively, these observations establish sex as a major prognostic factor underlying neuronal dysfunction in NF1, and suggest that sex should be considered when interpreting future preclinical and clinical study results.
© 2014 Child Neurology Society/American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24375753      PMCID: PMC4172335          DOI: 10.1002/ana.24093

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Authors:  Jessica Amlin-Van Schaick; Sungjin Kim; Karl W Broman; Karlyne M Reilly
Journal:  Mamm Genome       Date:  2011-12-08       Impact factor: 2.957

2.  The cognitive profile of preschool-aged children with neurofibromatosis type 1.

Authors:  Jennifer Sangster; E Arthur Shores; Sharon Watt; Kathryn N North
Journal:  Child Neuropsychol       Date:  2010-05-25       Impact factor: 2.500

3.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu
Journal:  Neuro Oncol       Date:  2012-04-03       Impact factor: 12.300

4.  Neurofibromin regulates G protein-stimulated adenylyl cyclase activity.

Authors:  Jiayuan Tong; Frances Hannan; Yinghua Zhu; Andre Bernards; Yi Zhong
Journal:  Nat Neurosci       Date:  2002-02       Impact factor: 24.884

5.  Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.

Authors:  Jacquelyn A Brown; Kelly A Diggs-Andrews; Scott M Gianino; David H Gutmann
Journal:  Mol Cell Neurosci       Date:  2011-08-26       Impact factor: 4.314

6.  Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.

Authors:  Kelly A Diggs-Andrews; Kazuhiro Tokuda; Yukitoshi Izumi; Charles F Zorumski; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 7.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

8.  The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians.

Authors:  S Baron-Cohen; S Wheelwright; R Skinner; J Martin; E Clubley
Journal:  J Autism Dev Disord       Date:  2001-02

9.  Sex chromosomes regulate nighttime sleep propensity during recovery from sleep loss in mice.

Authors:  J Christopher Ehlen; September Hesse; Lennisha Pinckney; Ketema N Paul
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

10.  A human-mouse conserved sex bias in amygdala gene expression related to circadian clock and energy metabolism.

Authors:  Li-Chun Lin; David A Lewis; Etienne Sibille
Journal:  Mol Brain       Date:  2011-05-04       Impact factor: 4.041

View more
  49 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

4.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

5.  Brain imaging findings and social/emotional problems in Israeli children with neurofibromatosis type 1.

Authors:  Rony Cohen; Tamar Steinberg; Liora Kornreich; Sharon Aharoni; Ayelet Halevy; Avinoam Shuper
Journal:  Eur J Pediatr       Date:  2014-07-16       Impact factor: 3.183

Review 6.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

7.  The effect of parental age on NF1 patients in Turkey.

Authors:  P Sharafi; B Anlar; S Ersoy-Evans; A Varan; O F Yılmaz; M Turan; S Ayter
Journal:  J Community Genet       Date:  2017-11-15

8.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

9.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.

Authors:  Chung-Ping Liao; Reid C Booker; Jean-Philippe Brosseau; Zhiguo Chen; Juan Mo; Edem Tchegnon; Yong Wang; D Wade Clapp; Lu Q Le
Journal:  J Clin Invest       Date:  2018-05-21       Impact factor: 14.808

10.  The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Authors:  Nicole M Warrington; Tao Sun; Jingqin Luo; Robert C McKinstry; Patricia C Parkin; Sara Ganzhorn; Debra Spoljaric; Anne C Albers; Amanda Merkelson; Douglas R Stewart; David A Stevenson; David Viskochil; Todd E Druley; Jason T Forys; Karlyne M Reilly; Michael J Fisher; Uri Tabori; Jeffrey C Allen; Joshua D Schiffman; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2014-11-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.